ILIris Tien-Lynn Lee

Iris Tien-Lynn Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iris Tien-Lynn Lee has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Nathanael Koelper

    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

    7 shared publications
  • Anuja Dokras

    Department of Obstetrics and Gynecology, University of Pennsylvania , Philadelphia, PA 19104

    5 shared publications
  • Anuja Dokras

    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, USA

    4 shared publications
  • Suneeta Senapati

    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

    4 shared publications
  • Dara S. Berger

    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

    3 shared publications
  • Kurt T. Barnhart

    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania

    3 shared publications

Latest Publications

  • Pregnancy and Delivery Outcomes Associated With Idiopathic Intracranial Hypertension in the United States

    by Amy Durand, Alan Y. Huang, Iris T. Lee, Sunni Mumford, Grant T. Liu, Ali G. Hamedani

  • Open Access

    Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome

    by Iris T Lee, Daniel E Soffer, Alan T Remaley, Martin P Playford, Nehal N Mehta, Christos Coutifaris, Richard S Legro, Anuja Dokras

    Context: Combined oral contraceptives (OCPs) and metformin are commonly used in patients with polycystic ovary syndrome (PCOS), who are at elevated risk of dyslipidemia and cardiovascular disease (CVD), but their effects on advanced lipid phenotyping remain unclear. Objective: To examine the impact of OCPs and metformin on (1) lipoproteins, (2) apolipoproteins, and (3) cholesterol efflux capacity (CEC, marker of HDL function). Design: Secondary analysis of the COMET-PCOS randomized clinical trial. Setting: Two tertiary care reproductive endocrinology clinics. Patients or Other Participants: Patients with hyperandrogenic PCOS and elevated BMI with paired serum samples for lipoprotein/apolipoprotein analysis (n = 180) and cholesterol efflux capacity (n = 129). Intervention(s): 24 weeks of metformin, OCP, or OCP + metformin. Main Outcome Measure(s): Change in HDL particles (HDL-P), low-density lipoprotein particles (LDL-P), triglyceride-rich lipoprotein particles (TRL-P); apolipoproteins A-I, B, and C-III; and CEC. Results: HDL-P concentration increased in the OCP and OCP + metformin arms, while atherogenic small LDL-P increased slightly. Metformin had a largely neutral effect on advanced lipid phenotyping. Cholesterol efflux capacity increased in the OCP arm, though this was attenuated when adjusting for change in ApoA-I (adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17), which increased in all arms. Conclusions: In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin. These findings do not support or refute the cardiovascular risk-benefit of OCP use in PCOS and highlight the need for studies evaluating long-term clinical outcomes.

  • Open Access

    Social deprivation, race, and metabolic syndrome in patients with polycystic ovary syndrome

    by Iris T Lee, Shakira King, Naria Sealy, John Rees, Sunni L Mumford, Stefanie N Hinkle, Anuja Dokras

    Context: Social determinants of health (SDoH) are a key contributor to cardiovascular disease (CVD) risk, including metabolic syndrome (MetSyn), as well as racial disparities in that risk. It is unknown if SDoH are associated with MetSyn in women with polycystic ovary syndrome (PCOS), who have a high risk of CVD. Furthermore, it is unclear if SDoH contributes to the Black-White disparity in MetSyn among women with PCOS. Objective: To assess the association between the Social Deprivation Index (SDI; a proxy for SDoH) and the development of new-onset MetSyn in women with PCOS and whether SDI plays a role in the racial disparity in MetSyn. Design: Longitudinal cohort study. Setting: Tertiary care center. Patients or Other Participants: Women with hyperandrogenic PCOS and 2+ assessments for MetSyn 3 years apart. Intervention(s): None. Main Outcome Measure(s): Development of new-onset MetSyn; proportion of association between race and MetSyn attributable to SDI. Results: Two hundred twenty-two participants were followed for a median of 7 years; 43.7% developed new-onset MetSyn. High SDI, indicating greater social deprivation, was associated with an increased risk of developing MetSyn (adjusted relative risk 1.42, 95% confidence interval 1.07-1.91 adjusting for age), as was Black race. The proportion of the association between race and new-onset MetSyn explained by SDI was 21%. Conclusion: High social deprivation is associated with increased risk of new-onset MetSyn and may contribute to the higher risk in Black compared to White women with PCOS. These results highlight the importance of considering SDoH, particularly in an already high-risk population.


  • Racial/ethnic variation in ovarian responsiveness and live birth after in vitro fertilization

    by Iris T. Lee, Nathanael Koelper, Monica Mainigi, Dara S. Berger, Suneeta Senapati


  • Vitamin D binding protein and reproductive outcomes

    by Iris Tien-Lynn Lee, Andrew N. Hoofnagle, Richard S. Legro, Michael P. Diamond, Nathanael Koelper, Stephen A. Krawetz, Samantha F. Butts


  • Association between markers of female adiposity and live birth among patients undergoing fertility treatment or attempting unassisted conception

    by Iris T Lee, Kurt T Barnhart, Wei-Ting Hwang, Stefanie N Hinkle, Erica Johnstone, James L Mills, Ellen C Caniglia, Enrique F Schisterman, Pauline Mendola, Ginny L Ryan, et al.

    STUDY QUESTION: Beyond BMI, are there better predictors of the impact of high female adiposity on reproductive outcomes in patients undergoing fertility treatment or attempting unassisted conception? SUMMARY ANSWER: Though BMI remains a predictor of fertility outcomes, alternative markers of adiposity, such as percent body fat, provide distinct information and may be more strongly associated with outcomes than BMI. WHAT IS KNOWN ALREADY: Elevated BMI is associated with a lower probability of live birth, though randomized trials have not consistently demonstrated the efficacy of weight loss for increasing live birth among patients utilizing infertility treatment. STUDY DESIGN, SIZE, DURATION: This was a secondary analysis of data gathered from 2013 to 2017 during the Folic Acid and Zinc Supplementation Trial (FAZST). Participants in FAZST included 2370 heterosexual couples seeking infertility care at four US fertility centers. Couples were followed for 9 months while undergoing fertility treatments or attempting unassisted conception, with up to 9 additional months of follow-up if pregnancy occurred. PARTICIPANTS/MATERIALS, SETTING, METHODS: For inclusion in the present study, female participants must have had at least one marker of adiposity measured at their baseline visit for FAZST. The primary exposure was high adiposity (defined by commonly used cutoffs in the literature) by each of five markers: BMI, percent body fat measured by dual-energy X-ray absorptiometry (DXA), serum leptin, serum adiponectin/leptin ratio, and waist circumference. Of the participants in FAZST, BMI was available for 99.6%, percent body fat for 7.3% (DXA only offered to 218 participants at two study sites between 2016 and 2017), leptin for 89.7%, adiponectin/leptin ratio for 89.7%, and waist circumference for 90.9%. Generalized linear models including age, race, parity, education, physical activity, male partner BMI ≥30 kg/m2, and Healthy Eating Index were used to estimate the relative risk of live birth. MAIN RESULTS AND THE ROLE OF CHANCE: High adiposity by BMI was associated with decreased probability of live birth (adjusted relative risk [aRR] 0.85, 95% CI 0.74–0.98). The other markers demonstrated similar associations, though a stronger effect size was seen with percent body fat (aRR 0.34, 95% CI 0.22–0.55). In an analysis by tertile, even moderately elevated percent body fat was associated with a decrease in live birth. When stratifying by infertility treatment status, associations were attenuated for most markers in the group utilizing infertility treatment, though percent body fat remained significantly associated with live birth. However, this marker was only available in a subset of participants. LIMITATIONS, REASONS FOR CAUTION: Only a subset of participants underwent DXA scans and had data on percent body fat, limiting the generalizability of the finding that this marker was most strongly associated with live birth. There were few participants with low BMIs, limiting the ability to draw conclusions on how low adiposity may affect reproductive outcomes. Findings may not be generalizable to the non-infertility population. WIDER IMPLICATIONS OF THE FINDINGS: The findings support prior data that high adiposity is associated with a lower probability of live birth. While most markers of adiposity performed similarly to BMI, there may be a role for percent body fat as an alternative assessment of adiposity, particularly among patients utilizing infertility treatment. STUDY FUNDING/COMPETING INTEREST(S): The FAZST and Impact of Diet, Exercise, and Lifestyle studies were supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (contracts HHSN275201200007C, HHSN275201500001C, HHSN275201300026I/HHSN27500008, and HHSN275201300026I/HHSN27500018). There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: NCT00467363 (secondary analysis).


  • Prediction of menstrual cycle phase using cross-sectional measurements of reproductive hormones

    by Iris T. Lee, Jessica Wu, Nathanael Koelper, Sunni L. Mumford, Kurt T. Barnhart, Andrea H. Roe


  • Depression, Anxiety, and Risk of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Longitudinal Study

    by Iris T Lee, John Rees, Shakira King, Anne Kim, Tess Cherlin, Stefanie Hinkle, Sunni L Mumford, Anuja Dokras

    Context Patients with polycystic ovary syndrome (PCOS) are at high risk of depression, anxiety, and metabolic syndrome (MetSyn), a key predictor of cardiovascular disease. The impact of depression and/or anxiety on MetSyn is unknown in this population. Objective To compare the risk of developing MetSyn in patients with PCOS with and without a history of depression and/or anxiety. Methods Retrospective longitudinal cohort study (2008-2022) with median follow-up of 7 years at a tertiary care ambulatory practice. Patients with hyperandrogenic PCOS and at least 2 evaluations for MetSyn ≥3 years apart (n = 321) were included. The primary outcome was risk of developing MetSyn. We hypothesized that this risk would be higher with a history of depression and/or anxiety. Results At the first visit, 33.0% had a history of depression and/or anxiety, with a third prescribed antidepressants or anxiolytics. Depression and/or anxiety increased risk of developing MetSyn during the study period (adjusted hazard ratio [aHR] 1.45, 95% CI 1.02-2.06, P = .04) with an incidence of MetSyn of 75.3 compared with 47.6 cases per 100 person-years among those without (P = .002). This was primarily driven by depression (aHR 1.56, 95% CI 1.10-2.20, P = .01). Conclusion Patients with PCOS and depression and/or anxiety have a high risk of developing MetSyn, with a stronger association between depression and MetSyn. Our findings highlight the urgent need for guideline-directed screening for depression and anxiety at time of diagnosis of PCOS as well as screening at subsequent visits to facilitate risk stratification for metabolic monitoring and early intervention in this high-risk group.


  • VARIATION IN PRACTICE PATTERNS SURROUNDING VITAMIN D TESTING AND SUPPLEMENTATION AMONG INFERTILITY PATIENTS

    by Iris Tienlynn. Lee, Marissa Steinberg Weiss, Daniel Miranian, Sreya Pattipati, Simran Rajpal, Caitlin Elizabeth Martin, Sunni L. Mumford